D. Boger, J.‐H. Chen
1997
Citations
0
Influential Citations
8
Citations
Journal
Bioorganic & Medicinal Chemistry Letters
Abstract
Abstract The preparation and preliminary evaluation of 2 , an analog of sandramycin, are detailed. Although 2 was typically 4–10x less potent than sandramycin against leukemia cell lines, it was found to be 1–10,000x more potent against melanomas, carcinomas, and adenocarcinomas exhibiting typical IC 50 values of 200-1 pM and placing it among the most potent agents identified to date.